Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

Families file wrongful death lawsuit against Camp Mystic after six young girls died in Guadalupe River flooding, alleging ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Me ...

Q3 2025 Earnings Call Transcript November 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-1.40538, expectations were $-1.91. Operator: Good morning, ladies and ...

R&D Pipeline -- IND-enabling activities for a PSMA-targeted ADC are on track for completion by year-end, further expanding the development portfolio.

Company continues growth momentum, reduces net loss 90.3% over prior year quarter, and accelerates path to Adjusted EBITDA breakeven ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Think your home is your safe haven? Unfortunately, that cozy feeling might be masking some serious hazards lurking in plain ...

Papcemias FDA Approval -- Granted full FDA approval in August with the first and only available treatment for all adults with recurrent respiratory papillomatosis (RRP); label is broad with no ...

Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent ...

She and her partner were being evicted after falling behind on rent and pondered which option could help: shelters, hotels, ...